Investigators → Thomas W. Halvorsen
ORA-SE-FLA · Southeast Division (Florida District)
Strictness Percentile: 64th
Thomas W. Halvorsen — FDA Investigator Citation Profile
Focuses heavily on 21 CFR 820.100(a) and 21 CFR 820.198(a). Expect a request for your Approved Supplier List, raw component identity testing chromatograms, and last 24 months of OOS/CAPA logs within the first 2 hours of opening conference.
Top Cited Clauses: 21 CFR 820.100(a), 21 CFR 820.198(a), 21 CFR 111.75(c)
Simulate Inspection by Thomas W. Halvorsen →
Recent Form 483s Linked to Thomas W. Halvorsen
TAILSTORM HEALTH INC (2026-08-28) · 3 observations
View 483 →Apollo Care LLC (2026-07-28) · 3 observations
View 483 →PQ Pharmacy LLC (2026-06-01) · 3 observations
View 483 →Richmond VA Medical Center (2026-05-12) · 3 observations
View 483 →Alkem Laboratories Limited (2026-05-01) · 3 observations
View 483 →Novel Laboratories, Inc. d.b.a Lupin Somerset (2026-04-17) · 3 observations
View 483 →Allure Labs, LLC (2026-03-27) · 3 observations
View 483 →Newton Laboratories, Inc. (2026-03-26) · 3 observations
View 483 →Bora Pharmaceuticals Injectables Inc (2026-03-20) · 3 observations
View 483 →Veterinary Pharmacy Corporation (2026-03-19) · 3 observations
View 483 →SCA Pharmaceuticals LLC (2026-03-13) · 3 observations
View 483 →Linde Industrial Gas (2026-03-11) · 3 observations
View 483 →Dxn Pharmaceutical Sdn Bhd (2026-03-06) · 3 observations
View 483 →BioLife Plasma Services L.P. (2026-03-04) · 3 observations
View 483 →Hillyard GMP (2026-02-27) · 3 observations
View 483 →